

AHI Announces AGM Results

Advanced Health Intelligence Ltd (ASX:AH1) (“AHI” or “the Company”) is pleased to announce the results of today’s Annual General Meeting (“AGM”) in accordance with ASX Listing Rule 3.13.2.

All resolutions contained in the Notice of Annual General Meeting that was released to AHI’s ASX market announcement platform on 30 October 2024 were passed on a poll of shareholder votes. The exception to this is Resolution 1, as the AGM has been adjourned to a later date so that Resolution 1 can be considered once shareholders have had the opportunity to consider the Company’s 2024 Annual Report.

As the Company previously advised on 25 November 2024, the 2024 Annual Report is yet to be released. The Company will provide shareholders with an update once the 2024 Annual Report has been lodged and a date for the resumption of the AGM has been confirmed.

A summary of the Proxy Votes and Poll Results from today’s AGM is attached to this announcement.

This announcement has been approved by the Chairman and CEO of Advanced Health Intelligence Ltd.

For more information, contact: .

Scott Montgomery
Chief Executive Officer
Advanced Health Intelligence Ltd
E: admin@ahi.tech

Vlado Bosanac
Founder/Head of Strategy
Advanced Health Intelligence Ltd
E: admin@ahi.tech

About Advanced Health Intelligence Ltd

Advanced Health Intelligence Ltd (‘AHI’) delivers scalable health assessment, risk stratification and digital triage capabilities to healthcare providers, insurers, employers, and government agencies worldwide via our proprietary technology and processes.

Since 2014, AHI has been delivering Health-tech innovation via a smartphone, starting with the world’s first on-device body dimensioning capability. AHI has developed a patented technology, showcasing the next frontier in digitising healthcare with a suite of componentised solutions, culminating in:

- Body dimension and composition assessment to identify the comorbidities of obesity, such as diabetes risk estimates.
- Blood biomarker prediction, including HbA1C, HDL, LDL, and 10-year mortality risk.
- Transdermal Optical Imaging to return vital signs and cardiovascular disease risk estimates.
- On-device dermatological skin identification across 588 skin conditions across 133 categories (Inc. Melanoma); and
- Assisting partners in delivering personalised therapeutic and non-therapeutic health coaching to improve daily habits and build health literacy.

Our world-class team of subject matter experts in machine learning, AI, computer vision, and medically trained data scientists ensure that AHI’s technology is at the forefront of innovation and the needs of our consumers.

Market Announcement
November 29, 2024



With a focus on impact at scale, AHI is proud to showcase this milestone in digital healthcare transformation, delivering a biometrically derived triage solution accessible on and via a smartphone. With these advanced

technologies, AHI helps its partners identify risks across their consumers and triage them into right-care pathways for proactive health management at a population scale.

For more information, please visit: www.ahi.tech

For personal use only

Disclosure of Proxy Votes

Advanced Health Intelligence Ltd

Annual General Meeting

Friday, 29 November 2024



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)			Results
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 ADOPTION OF REMUNERATION REPORT	-	51,652,576	50,950,402 98.64%	679,074 1.31%	738,845	23,100 0.04%	Resolution withdrawn			-
2 RE-ELECTION OF A DIRECTOR - PETER GOLDSTEIN	P	52,311,158	51,644,128 98.72%	643,930 1.23%	80,263	23,100 0.04%	52,633,638 98.79%	643,930 1.21%	80,263	Carried
3 RE-ELECTION OF A DIRECTOR - DR KATHERINE ISCOE	P	35,425,041	34,555,528 97.55%	849,313 2.40%	16,966,380	20,200 0.06%	35,542,138 97.67%	849,313 2.33%	16,966,380	Carried
4 RATIFICATION OF PRIOR ISSUE OF SHARES UNDER THE PRIOR PLACEMENT	P	51,889,960	51,090,255 98.46%	776,605 1.50%	1,461	23,100 0.04%	52,079,765 98.53%	776,605 1.47%	1,461	Carried
5 RATIFICATION OF PRIOR ISSUE OF SHARES TO ARIES FINANCE PTY LTD	P	52,389,960	51,648,491 98.58%	718,369 1.37%	1,461	23,100 0.04%	52,638,001 98.65%	718,369 1.35%	1,461	Carried
6 RATIFICATION OF PRIOR ISSUE OF SHARES TO ARIES FINANCE PTY LTD – LISTING RULE 7.1A	P	52,389,960	51,648,491 98.58%	718,369 1.37%	1,461	23,100 0.04%	52,638,001 98.65%	718,369 1.35%	1,461	Carried
7 RATIFICATION OF PRIOR ISSUE OF SHARES TO ALEXANDER SEVERINO – LISTING RULE 7.1A	P	52,389,960	51,660,255 98.61%	706,605 1.35%	1,461	23,100 0.04%	52,649,765 98.68%	706,605 1.32%	1,461	Carried
8 RATIFICATION OF PRIOR ISSUE OF SHARES TO ADRIAN MUDRONJA – LISTING RULE 7.1A	P	52,389,960	51,534,969 98.37%	831,891 1.59%	1,461	23,100 0.04%	52,524,479 98.44%	831,891 1.56%	1,461	Carried

For personal use only



For personal use only

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)			Results
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
9 RATIFICATION OF PRIOR ISSUE OF SHARES TO KAP VISTA PTY LTD	P	52,389,960	51,593,205 98.48%	773,655 1.48%	1,461	23,100 0.04%	52,582,715 98.55%	773,655 1.45%	1,461	Carried
10 RATIFICATION OF PRIOR ISSUE OF TRANCHE 1 SHARES UNDER THE 2024 PLACEMENT – LISTING RULE 7.1	P	52,389,960	51,598,205 98.49%	768,655 1.47%	1,461	23,100 0.04%	52,587,715 98.56%	768,655 1.44%	1,461	Carried
11 RATIFICATION OF PRIOR ISSUE OF TRANCHE 1 SHARES UNDER THE 2024 PLACEMENT – LISTING RULE 7.1A	P	52,389,960	51,539,969 98.38%	826,891 1.58%	1,461	23,100 0.04%	52,529,479 98.45%	826,891 1.55%	1,461	Carried
12 RATIFICATION OF PRIOR ISSUE OF TRANCHE 2 SHARES UNDER THE 2024 PLACEMENT – LISTING RULE 7.1	P	52,389,960	51,539,969 98.38%	826,891 1.58%	1,461	23,100 0.04%	52,529,479 98.45%	826,891 1.55%	1,461	Carried
13 APPROVAL TO ISSUE TRANCHE 3 SHARES UNDER THE 2024 PLACEMENT	P	51,883,486	51,012,455 98.32%	847,931 1.63%	7,935	23,100 0.04%	52,001,965 98.40%	847,931 1.60%	7,935	Carried
14 APPROVAL TO ISSUE PLACEMENT OPTIONS	P	51,883,486	51,182,169 98.65%	669,981 1.29%	7,935	31,336 0.06%	52,179,915 98.73%	669,981 1.27%	7,935	Carried
15 APPROVAL TO INCREASE MAXIMUM SECURITIES UNDER THE COMPANY'S EMPLOYEE INCENTIVE PLAN	P	52,391,041	49,477,450 94.44%	2,890,491 5.52%	380	23,100 0.04%	50,266,960 94.56%	2,890,491 5.44%	200,380	Carried
16 APPROVAL OF 7.1A MANDATE	P	52,374,486	51,509,255 98.35%	833,895 1.59%	16,935	31,336 0.06%	52,507,001 98.44%	833,895 1.56%	16,935	Carried

